BAVARIAN NORDIC/S (OTCMKTS:BVNRY) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Wednesday, reports.

According to Zacks, “Bavarian Nordic A/S is a biotechnology company. It focused on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases. The company’s product pipeline consists of IMVAMUNE(R), PROSTVAC (R), MVA-BN Brachyury, CV-301, MVA-BN Filo which are in clinical trial stage. Bavarian Nordic A/S is headquartered in Kvistgaard, Denmark. “

OTCMKTS BVNRY traded down $0.38 on Wednesday, hitting $8.42. 300 shares of the company were exchanged, compared to its average volume of 464. The company’s 50 day moving average price is $8.69 and its 200-day moving average price is $7.59. The company has a debt-to-equity ratio of 0.22, a current ratio of 9.34 and a quick ratio of 9.01. The firm has a market capitalization of $852.98 million, a P/E ratio of -14.27 and a beta of 0.59. BAVARIAN NORDIC/S has a twelve month low of $5.92 and a twelve month high of $9.62.

BAVARIAN NORDIC/S (OTCMKTS:BVNRY) last issued its earnings results on Thursday, August 15th. The company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.03). The business had revenue of $15.26 million during the quarter, compared to analyst estimates of $19.80 million. BAVARIAN NORDIC/S had a negative net margin of 42.42% and a negative return on equity of 12.10%. As a group, equities analysts expect that BAVARIAN NORDIC/S will post -0.56 EPS for the current year.


Bavarian Nordic A/S, a biotechnology company, develops, manufactures, and commercializes a portfolio of cancer immunotherapies and vaccines for infectious diseases. The company markets non-replicating smallpox vaccine under the IMVAMUNE and IMVANEX names. It is also developing MVA-BN RSV, which is in Phase II clinical trials development stage for the prevention of respiratory syncytial virus; MVA-BN Filo that is in Phase III clinical trials for the treatment of Ebola and Marburg; and MVA-BN HPV that is in Phase I/IIa clinical trials to treat human papillomavirus.

Featured Story: Why do companies pay special dividends?

Get a free copy of the Zacks research report on BAVARIAN NORDIC/S (BVNRY)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for BAVARIAN NORDIC/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BAVARIAN NORDIC/S and related companies with's FREE daily email newsletter.